Managing Myths and Misconceptions: How to Ensure Attractive Acquisition Interest in Life Science Consulting

With recent funding pressures in the Biopharma sector during H1 2023, life science consultancies have faced squeezed profit margins and tighter budgets, challenging their organic growth. Yet, consulting remains a resilient sector with scalable and lucrative business models, continuing to attract private equity (PE) and strategic investors.

When evaluating potential targets, investors consider a range of factors including financial sustainability, market positioning, industry consolidation, growth potential, operational management, and exit strategies.

After interviewing 24 life science strategy consultancies, it is clear there is strong activity from boutique and mid-sized firms planning expansion via acquisitions, and significant investor interest in this fragmented market. Approximately 46% of these consultancies are actively engaged with investors, with 75% reviewing growth strategies to attract PE or strategic acquisition opportunities. However, 29% of firms feel they are not ready to sell due to common misconceptions.

Buy-Side: The Investor Perspective

Consulting firms offer diversified and profitable revenue streams, making them highly appealing to investors. During target identification and prioritisation, buyers typically evaluate:

• Profitability: EBITDA, revenue growth, and operational efficiency
• Strategic Expansion: Niche capabilities (e.g., Pricing & Market Access) to broaden offerings and enter new markets
• Portfolio Diversification: Bolt-on acquisitions to create market synergies and strengthen existing portfolios
• Technology & Innovation: Proprietary data platforms that deliver scalable, innovative solutions
• Brand Reputation: Strong market credibility and a clear value proposition
• Exit Strategy: Defined paths for returns, either through IPO or sale to strategic buyers

Among the 24 consultancies interviewed, 75% are reviewing their growth strategies with a view to PE investment or strategic acquisition. However, 29% believe they are “not ready to sell” due to misconceptions about the process.

Market Snapshot: Boutique and Mid-Sized Firms

• 46% are in active discussions with private investors
• 55% specialise exclusively in Pricing & Market Access Strategy
• 27% specialise exclusively in Commercial, Corporate, or Product Strategy
• 18% offer both Commercial Strategy and Market Access
• 21% have a proprietary data platform

Preparing for Investment: Four Common Myths

Unfounded misconceptions can lead to missed opportunities or less favourable outcomes. From our most recent discussions with PE-backed consultancies who are engaging in bolt-on strategic acquisitions, we identified the four most common misconceptions formed during the target identification stage:

• Revenue Equals Value: High revenue alone does not guarantee acquisition interest. Investors prioritise profitability and potential synergies. A lower-revenue, high-EBITDA firm may attract higher multiples.
• The Right Buyer Will Find You: Relying solely on inbound interest can limit options. Engaging advisors and networking with investors ensures your value proposition is visible and due diligence runs efficiently.
• Size Determines Success: Some boutique consultancies believe they need a minimum headcount to attract buyers. In reality, investors focus on sustainable profits, growth potential, and operational performance rather than size alone.
• Not Knowing Your End Goal: Strategic and financial buyers have different priorities. Strategic acquirers focus on synergies, market expansion, and long-term growth, whereas financial buyers emphasise operational optimisation and exit returns. Understanding your end goal is critical to aligning with the right investor.

Conclusion

Boutique and mid-sized life science consultancies are well-positioned to attract acquisitions, provided they address misconceptions, demonstrate profitability, and define clear strategic and exit goals. Proactive planning and engagement with investors are essential to maximise deal outcomes in today’s competitive market.